Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2,000
Single User License Price INR 135
Corporate User License Price USD 6,000
Corporate User License Price INR 405
Site License Price USD 4,000
Site License Price INR 270
Request a Quote

Report Title

Diabetic Foot Ulcers - Pipeline Review, H1 2018

Quote Request for License Type
License Type Price  
Single User License USD 2,000
Site License USD 4,000
Enterprise Wide License USD 6,000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Diabetic Foot Ulcers - Pipeline Review, H1 2018


Quote Request for License Type
License Type Price  
Single User License USD 2,000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Diabetic Foot Ulcers - Pipeline Review, H1 2018

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Diabetic Foot Ulcers - Pipeline Review, H1 2018



Executive Summary

Diabetic Foot Ulcers - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers - Pipeline Review, H1 2018, provides an overview of the Diabetic Foot Ulcers (Metabolic Disorders) pipeline landscape.

Diabetic foot ulcers are sores that occur on the feet of people with Type 1 Diabetes and Type 2 Diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg, pain, walking with difficulty, discoloration in feet: black, blue, or red, cold feet and fever, skin redness or swelling, or other signs of infection. The predisposing factors include diabetic neuropathy, peripheral vascular disease, a foot deformity and history of tobacco use disorder.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Foot Ulcers - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 13, 9, 2, 15, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers (Metabolic Disorders).

- The pipeline guide reviews pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Diabetic Foot Ulcers (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Diabetic Foot Ulcers (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Diabetic Foot Ulcers (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

Introduction 5

Diabetic Foot Ulcers - Overview 6

Diabetic Foot Ulcers - Therapeutics Development 7

Diabetic Foot Ulcers - Therapeutics Assessment 17

Diabetic Foot Ulcers - Companies Involved in Therapeutics Development 26

Diabetic Foot Ulcers - Drug Profiles 37

Diabetic Foot Ulcers - Dormant Projects 119

Diabetic Foot Ulcers - Discontinued Products 122

Diabetic Foot Ulcers - Product Development Milestones 123

Appendix 132

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Diabetic Foot Ulcers, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

List of Tables

Number of Products under Development for Diabetic Foot Ulcers, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Diabetic Foot Ulcers - Pipeline by ANP Technologies Inc, H1 2018

Diabetic Foot Ulcers - Pipeline by Boston Therapeutics Inc, H1 2018

Diabetic Foot Ulcers - Pipeline by CardioVascular BioTherapeutics Inc, H1 2018

Diabetic Foot Ulcers - Pipeline by Chrysalis BioTherapeutics Inc, H1 2018

Diabetic Foot Ulcers - Pipeline by CytoTools AG, H1 2018

Diabetic Foot Ulcers - Pipeline by Energenesis Biomedical Co Ltd, H1 2018

Diabetic Foot Ulcers - Pipeline by EyeGene Inc, H1 2018

Diabetic Foot Ulcers - Pipeline by FirstString Research Inc, H1 2018

Diabetic Foot Ulcers - Pipeline by Genentech Inc, H1 2018

Diabetic Foot Ulcers - Pipeline by GlaxoSmithKline Plc, H1 2018

Diabetic Foot Ulcers - Pipeline by Human Stem Cells Institute, H1 2018

Diabetic Foot Ulcers - Pipeline by Izun Pharmaceuticals Corp, H1 2018

Diabetic Foot Ulcers - Pipeline by Lakewood-Amedex Inc, H1 2018

Diabetic Foot Ulcers - Pipeline by MallInckrodt Plc, H1 2018

Diabetic Foot Ulcers - Pipeline by MediWound Ltd, H1 2018

Diabetic Foot Ulcers - Pipeline by NovaLead Pharma Pvt Ltd, H1 2018

Diabetic Foot Ulcers - Pipeline by OliX Pharmaceuticals Inc, H1 2018

Diabetic Foot Ulcers - Pipeline by Oneness Biotech Co Ltd, H1 2018

Diabetic Foot Ulcers - Pipeline by Pherecydes Pharma SA, H1 2018

Diabetic Foot Ulcers - Pipeline by ProMetic Life Sciences Inc, H1 2018

Diabetic Foot Ulcers - Pipeline by Serodus ASA, H1 2018

Diabetic Foot Ulcers - Pipeline by Stempeutics Research Pvt Ltd, H1 2018

Diabetic Foot Ulcers - Pipeline by TechnoPhage SA, H1 2018

Diabetic Foot Ulcers - Pipeline by Topadur Pharma AG, H1 2018

Diabetic Foot Ulcers - Pipeline by USV Pvt Ltd, H1 2018

Diabetic Foot Ulcers - Pipeline by ViroMed Co Ltd, H1 2018

Diabetic Foot Ulcers - Dormant Projects, H1 2018

Diabetic Foot Ulcers - Dormant Projects, H1 2018 (Contd..1), H1 2018

Diabetic Foot Ulcers - Dormant Projects, H1 2018 (Contd..2), H1 2018

Diabetic Foot Ulcers - Discontinued Products, H1 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

ANP Technologies Inc

Boston Therapeutics Inc

CardioVascular BioTherapeutics Inc

Chrysalis BioTherapeutics Inc

CytoTools AG

Energenesis Biomedical Co Ltd

EyeGene Inc

FirstString Research Inc

Genentech Inc

GlaxoSmithKline Plc

Human Stem Cells Institute

Izun Pharmaceuticals Corp

Lakewood-Amedex Inc

MallInckrodt Plc

MediWound Ltd

NovaLead Pharma Pvt Ltd

OliX Pharmaceuticals Inc

Oneness Biotech Co Ltd

Pherecydes Pharma SA

ProMetic Life Sciences Inc

Serodus ASA

Stempeutics Research Pvt Ltd

TechnoPhage SA

Topadur Pharma AG

USV Pvt Ltd

ViroMed Co Ltd

Diabetic Foot Ulcers Therapeutic Products under Development, Key Players in Diabetic Foot Ulcers Therapeutics, Diabetic Foot Ulcers Pipeline Overview, Diabetic Foot Ulcers Pipeline, Diabetic Foot Ulcers Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand